The histopathologic report showed invasive ductal carcinoma in all patients, estrogen or progesterone receptor positivity in 10 patients (71.42%), and HER2 positivity (9 patients showed HER2 3+ on immunohistochemistry while 5 patients showed HER2 2+ and FISH positiveness). The gene discussed is ERBB2; the disease is invasive ductal breast carcinoma.